Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company founded in 2002 by Thomas Tuschl, Paul Schimmel, David Bartel, John Clarke, Phillip D. Zamore, Phillip Sharp and Robert Langer.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
June 5, 2020
FierceBiotech
With an FDA decision to come by the end of the year, Alnylam is offering a closer look at its RNA-silencing treatment for a rare kidney disorder. The drug, lumasiran, beat placebo at helping patients clear a substance called oxalate from their kidneys and lowered most patients' oxalate levels to normal or near-normal amounts.
BioSpace
June 7, 2020
BioSpace
Lumasiran Achieved Primary Endpoint with 53.5 Percent Mean Reduction in Urinary Oxalate Relative to Placebo and Showed a 65.4 Percent Reduction Relative to Baseline
Mark Terry
May 26, 2020
BioSpace
Alnylam Pharmaceuticals' lumasiran for a chronic kidney stone disease was granted Priority Review status by the U.S. Food and Drug Administration. It will have a target action date of December 3, 2020.
BioSpace
May 26, 2020
BioSpace
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) - the gene encoding glycolate oxidase (GO) - in development for the treatment o
May 22, 2020
BioSpace
Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020 - read this article along with other careers information, tips and advice on BioSpace
Todd Prussman
May 19, 2020
Boston Herald
Mayor Marty Walsh details Boston coronavirus reopening plans
December 10, 2018
WebWire
Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces today a Settlement and License Agreement with Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY). Alnylam will license patents from Silence and will pay Silence a tiered royalty on net sales of ONPATTROTMin the EU only ranging from 0.33 percent to 1.0 percent through 2023. All legal proceedings in all jurisd...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.